| __timestamp | Axsome Therapeutics, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 16758000 |
| Thursday, January 1, 2015 | 2419289 | 17793000 |
| Friday, January 1, 2016 | 6343648 | 18761000 |
| Sunday, January 1, 2017 | 7206691 | 19287000 |
| Monday, January 1, 2018 | 9351522 | 18707000 |
| Tuesday, January 1, 2019 | 13598030 | 20893000 |
| Wednesday, January 1, 2020 | 28896749 | 25678000 |
| Friday, January 1, 2021 | 66646205 | 29665000 |
| Saturday, January 1, 2022 | 159253661 | 43628000 |
| Sunday, January 1, 2023 | 323123000 | 69135000 |
| Monday, January 1, 2024 | 411359000 |
Cracking the code
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Axsome Therapeutics, Inc. and Geron Corporation, from 2014 to 2023. Over this period, Axsome Therapeutics has seen a staggering increase in SG&A expenses, growing by over 23,000% from 2014 to 2023. In contrast, Geron Corporation's expenses have increased by approximately 312%, indicating a more conservative growth strategy. Notably, Axsome's expenses surged significantly post-2020, reflecting its aggressive expansion and investment in marketing and administrative capabilities. Meanwhile, Geron's steady rise suggests a focus on sustainable growth. These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for potential investors and industry analysts.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Geron Corporation
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. or Verona Pharma plc: Who Manages SG&A Costs Better?
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation